• Direct.Latest news about the coronavirus

  • Salud.Moderna ensures that its vaccine against Covid-19 activates a strong immunity in older people

  • Covid-19: the latest advances in 'anticovid' vaccines

Closer.

While an adverse effect puts Johnson & Johnson trials on hold, Moderna has

submitted the 'papers' to formally request the approval

of its candidate in Europe.

In this way, the European Medicines Agency (EMA) will be able to evaluate the mRNA-1273 vaccine in order to request a marketing authorization from the European Union.

In this sense, the EMA's confirmation highlights Moderna's commitment to make the vaccine

accessible to the entire European Union

.

Moderna's request for authorization will include

updated clinical information on mRNA-1273

.

It includes the results obtained from a preclinical study on the virus, as well as the provisional analysis of Phase 1 of the study of mRNA-1273 in adults (18-55 years) and the elderly (56-70 and 71+ years ) published in the

New England Journal of Medicine

.

In this trial, results in

older

people

showed that the vaccine produces neutralizing antibodies to

the virus at levels similar to those seen in younger adults, with side effects roughly on par with flu vaccines.

In Europe, the company is working with its strategic partners, the Swiss, Lonza, and the Spanish, ROVI, to manufacture and supply the vaccine.

It is a supply chain dedicated entirely to supporting Europe and countries that, apart from the United States, have purchasing agreements with Moderna.

Thus, a total of 22,194 participants of the COVE phase IIO study of the candidate vaccine, mRNA-1273, have received the second dose of the vaccine as of October 9.

On the other hand, Moderna announced yesterday that the Canadian Ministry of Health will begin the evaluation of its candidate.

To date, this candidate has had no serious adverse problems.

In the

New England

,

mild side effects,

including headache, fatigue, body aches, chills, and injection site pain, were rated as mild to moderate.

However, in at least two cases, the volunteers had severe reactions.

One developed a grade three fever, which is classified as 39 ° C or higher, after receiving the lowest dose of the vaccine.

Another developed such severe fatigue that it temporarily prevented daily activities.

Side effects usually occurred shortly after receiving the vaccine and resolved quickly.

According to the criteria of The Trust Project

Know more

  • Science and Health

  • Covid 19

  • Vaccinations

  • Coronavirus

  • United States

  • Infectious diseases

  • Respiratory diseases

  • Pharmacology

This is how dexamethasone works, the 'anticovid' drug that Donald Trump receives

Health How does the new cocktail of antibodies that Trump receives?

ImmunizationA Health Committee will decide who will be vaccinated first against Covid-19

See links of interest

  • News

  • Translator

  • Programming

  • Films

  • Topics

  • Ukraine - Spain, live

  • Valencia Basket - Barça

  • Stage 11: Porto Sant'Elpidio-Rimini, live

  • Real Madrid - Khimki Moscow